Eli Lilly (LLY) is going after two more drug compounders that continue to make and sell copies of its weight loss drug despite a March court order against it, multiple media outlets reported Tuesday.
The company's latest lawsuits were filed against Strive Pharmacy and Empower Clinic Services, Reuters reported. The company is demanding that compounders stop selling products with tirzepatide, the active ingredient in its weight loss and diabetes drugs Zepbound and Mounjaro.
Lilly had filed lawsuits against over two dozen medical spas, wellness centers, and compounding pharmacies, according to the report.
The company also plans to send around 50 cease-and-desist letters asking compounders and telehealth companies to confirm by April 8 that they have stopped manufacturing and selling all forms of compounded tirzepatide, Bloomberg reported.
Lilly did not immediately reply to a request for comment from MT Newswires.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。